# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Charlotte Brontë (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI025-SYN
- Date: 2026-03-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Thwaite, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Prenatal visit at 17 weeks. **S**

## History of present illness

Ms. Brontë returns at 17 weeks 1 day. She has not vomited for ten days and has needed no ondansetron for two weeks. Mild nausea comes on only when she is tired. She eats well and walks out most afternoons. She takes doxylamine-pyridoxine four tablets a day, aspirin 81 mg at bedtime without bruising or bleeding, and folic acid. Her PUQE-24 score is 4. She has no palpitations, headache, visual change, pain, bleeding, or urinary symptoms. She is writing most mornings and feels hopeful. **S**

| Element | Detail |
|---|---|
| Interval change | No vomiting for ten days; no ondansetron for two weeks |
| PUQE-24 | 4 (mild), down from 14 at its worst |
| Medications | Doxylamine-pyridoxine four tablets a day, aspirin 81 mg, folic acid |
| Mood | Hopeful; EPDS 5 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No vomiting; mild nausea only when tired; bowels regular |
| Cardiovascular | Negative | No palpitations |
| Neurological | Negative | No headache or visual change |
| Genitourinary | Negative | No bleeding or urinary symptoms |
| Psychiatric | Negative | Mood good; EPDS 5 |

5 systems reviewed. **S**

## Current medications

- Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe) **S**
- Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day) **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/68 mmHg; pulse 80 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 46.2 kg; BMI 20 kg/m². All vital signs are synthetic.

Hemoglobin: 11.6 g/dL; TSH: 0.92 mIU/L; Free T4: 1.1 ng/dL; EPDS: 5. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.8 g/dL at baseline, 11.6 g/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 46.2 kg |
| Neck | Thyroid not enlarged |
| Abdomen | Fundus midway between the pubic bone and the umbilicus |
| Fetal | Fetal heart 150 per minute by Doppler |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hyperemesis gravidarum, settled** (O21.1). PUQE-24 score 4 and weight 46.2 kg, back above her pre-pregnancy weight. Hemoglobin 11.6 g/dL. **S**
   - Ondansetron stopped.
   - Taper doxylamine-pyridoxine over two weeks: three tablets a day for a week, then two at bedtime for a week, then stop; restart at the last dose that worked if vomiting returns.
   - Call if vomiting returns and she cannot keep fluids down.
2. **Gestational transient thyrotoxicosis, resolved** (O99.281). TSH 0.92 mIU/L and free T4 1.1 ng/dL: normal as hCG has fallen; no treatment was needed. **S**
   - No further thyroid tests unless symptoms develop.
3. **First pregnancy at 38** (O09.519). Fetal heart 150 per minute; blood pressure 108/68 mmHg on aspirin. EPDS 5 with item 10 scored 0. **S**
   - Continue aspirin 81 mg at bedtime and folic acid; restart the iron-containing prenatal vitamin now that nausea has settled.
   - Detailed anatomy scan in three weeks.
   - Glucose challenge test at 24 to 28 weeks; Tdap at 27 to 36 weeks; repeat mood screen in the third trimester.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PUQE-24 score (recorded in the note; no LOINC code found) | Every visit while nausea and vomiting last | Completed today | 4 (mild) |
| Examination | Weight against pre-pregnancy weight (46.0 kg), pulse, blood pressure, and hydration | Every visit while nausea and vomiting last | Completed today | 46.2 kg, back above her pre-pregnancy weight; pulse 80 |
| Laboratory | TSH and free T4 | In hyperemesis gravidarum; repeat at 16 to 18 weeks if suppressed | Completed today | TSH 0.92 mIU/L and free T4 1.1 ng/dL: normal |
| Laboratory | Hemoglobin | At intake and again at 24 to 28 weeks; earlier after hemoconcentration | Completed today | 11.6 g/dL |
| Laboratory | Electrolytes, urea nitrogen, creatinine, and glucose | Until stable on oral intake | Not indicated | Not repeated: normal on oral intake |
| Medication safety | Antiemetic taper | When vomiting has stopped for a week | Completed today | Ondansetron stopped; doxylamine-pyridoxine taper over two weeks |
| Medication safety | Low-dose aspirin | Every visit | Completed today | Taken nightly; no bruising or bleeding |
| Survey | Perinatal mood screen | Each trimester | Completed today | EPDS 5; item 10 scored 0 |
| Imaging | Detailed anatomy scan | At 18 to 22 weeks | Due | Booked for 20 weeks |
| Examination | Blood pressure | Every prenatal visit | Completed today | 108/68 mmHg |
| Examination | Fetal heart | Every prenatal visit | Completed today | 150 per minute by Doppler |

## Goal progress

- Nausea and vomiting mild (PUQE-24 score 6 or less) and weight back to her pre-pregnancy 46.0 kg by about 17 weeks. Outcome by 2026-03-24: PUQE-24 score 4 and weight 46.2 kg at 17 weeks 1 day. **S**
- Hydration and electrolytes normal within two weeks of any admission. Outcome by 2026-02-10: Sodium, potassium, chloride, bicarbonate, magnesium, phosphate, and transaminases all normal nine days after discharge. **S**
- An informed choice about aneuploidy screening and diagnostic testing by 13 weeks. Outcome by 2026-02-24: Chose cell-free DNA screening (low risk) and the nuchal translucency scan (1.5 mm); declined diagnostic testing. **S**
- Low-dose aspirin started between 12 and 16 weeks if indicated. Outcome by 2026-02-24: Started at 13 weeks 1 day for two moderate risk factors. **S**
- Tuberculosis screening completed and explained by the second visit. Outcome by 2026-01-20: Interferon-gamma release assay negative; no latent infection; no chest radiograph needed. **S**
- Mood screened in each trimester, with support offered. Outcome by 2026-03-24: PHQ-9 5 at intake, EPDS 9 after the admission and 5 at 17 weeks; item 10 scored 0 each time. **S**

## Medication changes

- Stopped: Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea **S**

## Guideline basis

- ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024), Royal College of Obstetricians and Gynaecologists (BJOG)
- Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021), U.S. Preventive Services Task Force
- 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum (2017), American Thyroid Association (Thyroid)
- Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum (Clinical Practice Guideline No. 4) (2023), American College of Obstetricians and Gynecologists

## Follow-up

- Anatomy scan in three weeks and prenatal visit in four weeks. **S**

